Compare JPMorgan Equity Premium Income ETF (JEPI) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs Mesoblast Limited — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.79 (market cap $45.55B), while Mesoblast Limited trades at $14.32 (market cap $1.75B). The key difference: JPMorgan Equity Premium Income ETF is far larger — about 26× Mesoblast Limited's market cap, and JPMorgan Equity Premium Income ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Equity Premium Income ETF for 56 Days and Mesoblast Limited for 14 Days on average.
| JEPI | MESO | |
|---|---|---|
Market Cap | $45.55B | $1.75B |
Volume | 3,820,809 | 239,027 |
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $20.96 |
52-Week Low | $55.29 | $13.19 |
Typical Hold Time | 56 Days | 14 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $56.73, up 0.5% with a bearish technical signal from moving averages. The ETF maintains consistent monthly dividend distributions, with recent payments of $0.37 in August and July 2026. Technical indicators show neutral oscillators with key support at $56 and resistance at $57. Recent news highlights JEPI's role in income strategies and institutional interest.
The covered-call strategy provides income but may limit upside during rallies. Institutional ownership growth signals confidence, though the bearish technical outlook and income-focused strategy suggest moderate growth potential with steady dividend income as the primary appeal.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
